{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:18:10Z","timestamp":1792145890542,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T00:00:00Z","timestamp":1530921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T00:00:00Z","timestamp":1530921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15H06719"],"award-info":[{"award-number":["15H06719"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K19786"],"award-info":[{"award-number":["16K19786"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["P50 AA022537"],"award-info":[{"award-number":["P50 AA022537"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1038\/s41386-018-0143-4","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T05:03:33Z","timestamp":1530939813000},"page":"443-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity"],"prefix":"10.1038","volume":"44","author":[{"given":"Mario","family":"de la Fuente Revenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Toneatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryum K.","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Wolstenholme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonz\u00e1lez-Maeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,7]]},"reference":[{"key":"143_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrn.2017.125","volume":"18","author":"R Birnbaum","year":"2017","unstructured":"Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci. 2017;18:727\u201340.","journal-title":"Nat Rev Neurosci"},{"key":"143_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635\u201345.","journal-title":"Lancet"},{"key":"143_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1192\/bjp.162.1.43","volume":"162","author":"TE Goldberg","year":"1993","unstructured":"Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 1993;162:43\u201348.","journal-title":"Br J Psychiatry"},{"key":"143_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.psychres.2016.10.085","volume":"247","author":"AP Husa","year":"2016","unstructured":"Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. 2016;247:130\u20138.","journal-title":"Psychiatry Res"},{"key":"143_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.schres.2014.06.035","volume":"158","author":"AP Husa","year":"2014","unstructured":"Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - an observational 9-year follow-up study. Schizophr Res. 2014;158:134\u201341.","journal-title":"Schizophr Res"},{"key":"143_CR6","doi-asserted-by":"crossref","unstructured":"Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131:185\u201396.","DOI":"10.1111\/acps.12374"},{"key":"143_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/npp.2015.3","volume":"40","author":"G Fervaha","year":"2015","unstructured":"Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, et al. Antipsychotics and amotivation. Neuropsychopharmacology. 2015;40:1539\u201348.","journal-title":"Neuropsychopharmacology"},{"key":"143_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"key":"143_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393\u2013406.","journal-title":"Annu Rev Med"},{"key":"143_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","volume":"17","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206\u201327.","journal-title":"Mol Psychiatry"},{"key":"143_CR11","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s00018-009-0130-3","volume":"66","author":"JL Moreno","year":"2009","unstructured":"Moreno JL, Sealfon SC, Gonzalez-Maeso J. Group II metabotropic glutamate receptors and schizophrenia. Cell Mol Life Sci. 2009;66:3777\u201385.","journal-title":"Cell Mol Life Sci"},{"key":"143_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","volume":"60","author":"F Nicoletti","year":"2011","unstructured":"Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011;60:1017\u201341.","journal-title":"Neuropharmacology"},{"key":"143_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","volume":"147","author":"M Fribourg","year":"2011","unstructured":"Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell. 2011;147:1011\u201323.","journal-title":"Cell"},{"key":"143_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.tins.2008.12.005","volume":"32","author":"J Gonzalez-Maeso","year":"2009","unstructured":"Gonzalez-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. 2009;32:225\u201332.","journal-title":"Trends Neurosci"},{"key":"143_CR15","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1016\/S0014-2999(00)00269-7","volume":"397","author":"WP Spooren","year":"2000","unstructured":"Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol. 2000;397:R1\u20132.","journal-title":"Eur J Pharmacol"},{"key":"143_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00213-007-0974-x","volume":"196","author":"ML Woolley","year":"2008","unstructured":"Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2\/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology. 2008;196:431\u201340.","journal-title":"Psychopharmacology"},{"key":"143_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tins.2015.06.002","volume":"38","author":"A Ellaithy","year":"2015","unstructured":"Ellaithy A, Younkin J, Gonzalez-Maeso J, Logothetis DE. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci. 2015;38:506\u201316.","journal-title":"Trends Neurosci"},{"key":"143_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.108.136861","volume":"326","author":"MJ Fell","year":"2008","unstructured":"Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther. 2008;326:209\u201317.","journal-title":"J Pharmacol Exp Ther"},{"key":"143_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102\u20137.","journal-title":"Nat Med"},{"key":"143_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-143","volume":"13","author":"DH Adams","year":"2013","unstructured":"Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry. 2013;13:143.","journal-title":"BMC Psychiatry"},{"key":"143_CR21","first-page":"758212","volume":"2014","author":"DH Adams","year":"2014","unstructured":"Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC. Pomaglumetad methionil (LY2140023 monohydrate) and Aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treat. 2014;2014:758212.","journal-title":"Schizophr Res Treat"},{"key":"143_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","volume":"31","author":"BJ Kinon","year":"2011","unstructured":"Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31:349\u201355.","journal-title":"J Clin Psychopharmacol"},{"key":"143_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cell.2013.12.020","volume":"156","author":"J Graff","year":"2014","unstructured":"Graff J, Joseph NF, Horn ME, Samiei A, Meng J, Seo J, et al. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell. 2014;156:261\u201376.","journal-title":"Cell"},{"key":"143_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10849","volume":"483","author":"J Graff","year":"2012","unstructured":"Graff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483:222\u20136.","journal-title":"Nature"},{"key":"143_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-pharmtox-011112-140216","volume":"53","author":"J Graff","year":"2013","unstructured":"Graff J, Tsai LH. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol. 2013;53:311\u201330.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"143_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature07925","volume":"459","author":"JS Guan","year":"2009","unstructured":"Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459:55\u201360.","journal-title":"Nature"},{"key":"143_CR27","doi-asserted-by":"crossref","unstructured":"Ibi D, Gonzalez-Maeso J. Epigenetic signaling in schizophrenia. Cell Signal. 2015; 27: 2131\u20136.","DOI":"10.1016\/j.cellsig.2015.06.003"},{"key":"143_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nrd3674","volume":"11","author":"CH Arrowsmith","year":"2012","unstructured":"Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11:384\u2013400.","journal-title":"Nat Rev Drug Discov"},{"key":"143_CR29","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nn.4616","volume":"20","author":"D Ibi","year":"2017","unstructured":"Ibi D, de la Fuente Revenga M, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, et al. Antipsychotic-induced Hdac2 transcription via NF-kappaB leads to synaptic and cognitive side effects. Nat Neurosci. 2017;20:1247\u201359.","journal-title":"Nat Neurosci"},{"key":"143_CR30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/nn.3181","volume":"15","author":"M Kurita","year":"2012","unstructured":"Kurita M, Holloway T, Garcia-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012;15:1245\u201354.","journal-title":"Nat Neurosci"},{"key":"143_CR31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1124\/mol.112.084582","volume":"83","author":"M Kurita","year":"2013","unstructured":"Kurita M, Moreno JL, Holloway T, Kozlenkov A, Mocci G, Garcia-Bea A, et al. Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice. Mol Pharmacol. 2013;83:1166\u201375.","journal-title":"Mol Pharmacol"},{"key":"143_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature06612","volume":"452","author":"J Gonzalez-Maeso","year":"2008","unstructured":"Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, et al. Identification of a serotonin\/glutamate receptor complex implicated in psychosis. Nature. 2008;452:93\u20137.","journal-title":"Nature"},{"key":"143_CR33","doi-asserted-by":"crossref","unstructured":"Holloway T, Gonzalez-Maeso J. Epigenetic mechanisms of serotonin signaling. ACS Chem Neurosci. 2015;6:1099\u2013109.","DOI":"10.1021\/acschemneuro.5b00033"},{"key":"143_CR34","doi-asserted-by":"crossref","unstructured":"Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry 2015;78:754-62.","DOI":"10.1016\/j.biopsych.2015.03.016"},{"key":"143_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonzalez-Maeso","year":"2007","unstructured":"Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439\u201352.","journal-title":"Neuron"},{"key":"143_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","volume":"493","author":"JL Moreno","year":"2011","unstructured":"Moreno JL, Holloway T, Albizu L, Sealfon SC, Gonzalez-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett. 2011;493:76\u201379.","journal-title":"Neurosci Lett"},{"key":"143_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1126\/science.1123432","volume":"313","author":"NV Weisstaub","year":"2006","unstructured":"Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzalez-Maeso J, Hornung JP, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science. 2006;313:536\u201340.","journal-title":"Science"},{"key":"143_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1126\/science.273.5275.645","volume":"273","author":"M Yokoi","year":"1996","unstructured":"Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, Katsuura G, et al. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science. 1996;273:645\u20137.","journal-title":"Science"},{"key":"143_CR39","volume-title":"Comparative Cytoarchitectonic Atlas of the C57BL\/6 and 129\/Sv Mouse Brains","author":"PR Hof","year":"2000","unstructured":"Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR. Comparative Cytoarchitectonic Atlas of the C57BL\/6 and 129\/Sv Mouse Brains. Amsterdam: Elsevier; 2000."},{"key":"143_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0014-2999(99)00827-4","volume":"390","author":"J Gonzalez-Maeso","year":"2000","unstructured":"Gonzalez-Maeso J, Rodriguez-Puertas R, Gabilondo AM, Meana JJ. Characterization of receptor-mediated [35S]GTPgammaS binding to cortical membranes from postmortem human brain. Eur J Pharmacol. 2000;390:25\u201336.","journal-title":"Eur J Pharmacol"},{"key":"143_CR41","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1136\/gutjnl-2014-307748","volume":"64","author":"DY Cao","year":"2015","unstructured":"Cao DY, Bai G, Ji Y, Traub RJ. Epigenetic upregulation of metabotropic glutamate receptor 2 in the spinal cord attenuates oestrogen-induced visceral hypersensitivity. Gut. 2015;64:1913\u201320.","journal-title":"Gut"},{"key":"143_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-015-0158-2","volume":"8","author":"M Motolese","year":"2015","unstructured":"Motolese M, Mastroiacovo F, Cannella M, Bucci D, Gaglione A, Riozzi B, et al. Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage. Mol Brain. 2015;8:66.","journal-title":"Mol Brain"},{"key":"143_CR43","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1017\/S1461145713000606","volume":"16","author":"JL Moreno","year":"2013","unstructured":"Moreno JL, Gonzalez-Maeso J. Preclinical models of antipsychotic drug action. Int J Neuropsychopharmacol. 2013;16:2131\u201344.","journal-title":"Int J Neuropsychopharmacol"},{"key":"143_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s40473-014-0013-2","volume":"1","author":"AD Forrest","year":"2014","unstructured":"Forrest AD, Coto CA, Siegel SJ. Animal models of psychosis: current state and future directions. Curr Behav Neurosci Rep. 2014;1:100\u201316.","journal-title":"Curr Behav Neurosci Rep"},{"key":"143_CR45","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/schbul\/sbp132","volume":"36","author":"M van den Buuse","year":"2010","unstructured":"van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull. 2010;36:246\u201370.","journal-title":"Schizophr Bull"},{"key":"143_CR46","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1073\/pnas.0500914102","volume":"102","author":"Y Morishima","year":"2005","unstructured":"Morishima Y, Miyakawa T, Furuyashiki T, Tanaka Y, Mizuma H, Nakanishi S. Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proc Natl Acad Sci USA. 2005;102:4170\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"143_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fncir.2014.00052","volume":"8","author":"R Shukla","year":"2014","unstructured":"Shukla R, Watakabe A, Yamamori T. mRNA expression profile of serotonin receptor subtypes and distribution of serotonergic terminations in marmoset brain. Front Neural Circuits. 2014;8:52.","journal-title":"Front Neural Circuits"},{"key":"143_CR48","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1017\/S1461145714000248","volume":"17","author":"HG Park","year":"2014","unstructured":"Park HG, Yu HS, Park S, Ahn YM, Kim YS, Kim SH. Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex. Int J Neuropsychopharmacol. 2014;17:1487\u20131500.","journal-title":"Int J Neuropsychopharmacol"},{"key":"143_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1073\/pnas.40.4.228","volume":"40","author":"DW Wooley","year":"1954","unstructured":"Wooley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA. 1954;40:228\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"143_CR50","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1038\/npp.2017.136","volume":"42","author":"AG Walker","year":"2017","unstructured":"Walker AG, Sheffler DJ, Lewis AS, Dickerson JW, Foster DJ, Senter RK, et al. Co-activation of metabotropic glutamate receptor 3 and beta-adrenergic receptors modulates cyclic-AMP and long-term potentiation, and disrupts memory reconsolidation. Neuropsychopharmacology. 2017;42:2553\u201366.","journal-title":"Neuropsychopharmacology"},{"key":"143_CR51","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1073\/pnas.1416196112","volume":"112","author":"AG Walker","year":"2015","unstructured":"Walker AG, Wenthur CJ, Xiang Z, Rook JM, Emmitte KA, Niswender CM, et al. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Proc Natl Acad Sci USA. 2015;112:1196\u2013201.","journal-title":"Proc Natl Acad Sci USA"},{"key":"143_CR52","doi-asserted-by":"publisher","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","volume":"21","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106S\u2013115S.","journal-title":"Neuropsychopharmacology"},{"key":"143_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1124\/jpet.111.183780","volume":"339","author":"PN Yadav","year":"2011","unstructured":"Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther. 2011;339:99\u2013105.","journal-title":"J Pharmacol Exp Ther"},{"key":"143_CR54","doi-asserted-by":"crossref","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544\u201353.","DOI":"10.1016\/j.biopsych.2014.11.015"},{"key":"143_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2015.04.003","volume":"43","author":"M Duvic","year":"2016","unstructured":"Duvic M, Dimopoulos M. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: a review of clinical studies. Cancer Treat Rev. 2016;43:58\u201366.","journal-title":"Cancer Treat Rev"},{"key":"143_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-017-0293-z","volume":"10","author":"J Maksymetz","year":"2017","unstructured":"Maksymetz J, Moran SP, Conn PJ. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Mol Brain. 2017;10:15.","journal-title":"Mol Brain"}],"updated-by":[{"DOI":"10.1038\/s41386-018-0255-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0143-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:03:38Z","timestamp":1684602218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0143-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,7]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["143"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0143-4","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,7]]},"assertion":[{"value":"22 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following the publication of this article Figs. 3b, c were published incorrectly. Also in sub-panel c of Fig. 4, \u2018Chronic cloza ine\u2019 should read \u2018Chronic clozapine\u2019","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}